Aeterna Zentaris (AEZS) Plans New Phase 3 Study of Macrilen Following Successful Meetings with FDA
Tweet Send to a Friend
Aeterna Zentaris Inc. (NASDAQ: AEZS) today announced plans to conduct a new, confirmatory Phase 3 clinical study to demonstrate the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
